Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients

Journal of Physiology and Pharmacology

Volumn 65, Issue 4, 2014, Pages 543-550

  Adamczyk Sowa, Monika ^a   Pierzchala, K ^a   Sowa, P ^a   Polaniak, R ^a   Kukla, M ^a   Hartel, M ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b MCD Voxel   (Poland)

Author keywords

Malondialdehyde; Melatonin; Multiple sclerosis; Multiple sclerosis impact scale; Quality of life; Reactive oxygen species; Superoxide dismutase

Indexed keywords

ANTIOXIDANT; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MALONALDEHYDE; MELATONIN; MITOXANTRONE; PEPTIDE; SUPEROXIDE DISMUTASE;

ADULT; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIOXIDANTS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MALONDIALDEHYDE; MELATONIN; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PEPTIDES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84906852906     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Mehta BK. New hypotheses on sunlight and the geographic variability of multiple sclerosis prevalence. J Neurol Sci 2010; 292: 5-10.
2. Golan D, Staun-Ram E, Glass-Marmor L, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 2013; 32: 180-185.
3. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010; 8: 228-242.
4. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251: 261-268.
5. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134: 1914-1924.
6. Tully M, Shi R. New insights in the pathogenesis of multiple sclerosis - role of acrolein in neuronal and myelin damage. Int J Mol Sci 2013; 14: 20037-20047.
7. Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor independent actions. Adv Med Sci 2007; 52: 11-28.
8. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15: 43-50.
9. Gonciarz M, Gonciarz Z, Bielanski W, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40.
10. Adamczyk-Sowa M, Sowa P, Pierzchala K, Polaniak R, Labuz-Roszak B. Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients. J Physiol Pharmacol 2012; 63: 683-690.
11. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.
12. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39: 99-104.
13. Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab 2013; 4: 13-24.
14. Srinivasan V, Spence DW, Trakh I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008; 15: 93-101.
15. Boe Lunde HM, Aae TF, Indrevag W, et al. Poor sleep in patients with multiple sclerosis. PLoS One 2012; 7: e49996. doi: 10.1371/journal.pone.0049996.
16. Cote I, Trojan DA, Kaminska M, et al. Impact of sleep disorder treatment on fatigue in multiple sclerosis. Mult Scler 2013; 19: 480-489.
17. Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 2008; 14: 1127-1130.
18. Caminero A, Bartolome M. Sleep disturbances in multiple sclerosis. J Neurol Sci 2011; 309: 86-91.
19. Hagan RM, Oakley NR. Melatonin comes of age? Trends Pharmacol Sci 1995; 16: 81-83.
20. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29). Brain 2001; 124: 962-973.
21. Jamroz-Wisniewska A, Papuc E, Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Stelmasiak Z. Validation of selected aspects of psychometry of the Polish version of the Multiple Sclerosis Impact Scale 29 (MSIS-29). Neurol Neurochir Pol 2007; 41: 215-222.
22. Melamud L, Golan D, Luboshitzky R, Lavi I, Miller A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci 2012; 314: 37-40.
23. Hedstrom AK, Akerstedt T, Hillert J, Olsson T, Alfredsson L. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol 2011; 70: 733-741.
24. Ghorbani A, Salari M, Shaygannejad V, Norouzi R. The role of melatonin in the pathogenesis of multiple sclerosis: a casecontrol study. Int J Prev Med 2013; 4 (Suppl. 2): S180-S184.
25. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005; 58: 840-846.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
27. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
28. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984; 142: 290-296.
29. Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G. Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int 2013; 63: 507-516.
30. Lin GJ, Huang SH, Chen SJ, Wang CH, Chang DM, Sytwu HK. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci 2013; 14: 11742-11766.
31. Miller E, Walczak A, Majsterek I, Kedziora J. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J Neuroimmunol 2013; 257: 97-101.
32. Natarajan R, Einarsdottir E, Riutta A, et al. Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. J Neuroimmunol 2012; 250: 106-110.
33. Miller E, Mrowicka M, Malinowska K, Kedziora J, Majsterek I. The effects of whole-body cryotherapy and melatonin supplementation on total antioxidative status and some antioxidative enzymes in multiple sclerosis patients. Pol Merkur Lekarski 2011; 31: 150-153.
34. Davitashvili D, Beridze M, Shakarishvili R, Kiziria M, Sanikidze T. The role of endogenous antiradical protective system in multiple sclerosis. Georgian Med News 2012; April: 11-19.
35. Ferretti G, Bacchetti T. Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci 2011; 311: 92-97.
36. Ljubisavljevic S, Stojanovic I, Vojinovic S, et al. Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks. Metab Brain Dis 2013; 28: 629-638.
37. Tasset I, Aguera E, Sanchez-Lopez F, et al. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 2012; 45: 440-444.
38. Bahamonde C, Conde C, Aguera E, et al. Elevated melatonin levels in natalizumab-treated female patients with relapsingremitting multiple sclerosis: relationship to oxidative stress. Eur J Pharmacol 2014; 730: 26-30.
39. Minagar A. Current and future therapies for multiple sclerosis. Scientifica (Cairo) 2013; 2013: 249101. doi: 10.1155/2013/249101.
40. Najafi MR, Toghianifar N, Etemadifar M, Haghighi S, Maghzi AH, Akbari M. Circadian rhythm sleep disorders in patients with multiple sclerosis and its association with fatigue: a case-control study. J Res Med Sci 2013; 18 (Suppl. 1): S71-S73.
41. Braley TJ, Chervin RD, Segal BM. Fatigue, tiredness, lack of energy, and sleepiness in multiple sclerosis patients referred for clinical polysomnography. Mult Scler Int 2012; 2012: 673936. doi: 10.1155/2012/673936.
42. Nagaraj K, Taly AB, Gupta A, Prasad C, Christopher R. Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life. J Neurosci Rural Pract 2013; 4: 278-282.
43. Papuc E, Stelmasiak Z. Factors predicting quality of life in a group of Polish subjects with multiple sclerosis: accounting for functional state, socio-demographic and clinical factors. Clin Neurol Neurosurg 2012; 114: 341-346.
44. Jones KH, Ford DV, Jones PA, et al. The physical and psychological impact of multiple sclerosis using the MSIS- 29 via the web portal of the UK MS Register. PLoS One 2013; 8: e55422. doi: 10.1371/journal.pone.0055422.
45. Akpinar Z, Tokgoz S, Gokbel H, Okudan N, Uguz F, Yilmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res 2008; 161: 253-257.
46. Chojnacki C, Walecka-Kapica E, Mokwinska M, et al. Influence of tianeptine on melatonin homeostasis and psychosomatic symptoms in patients with irritable bowel syndrome. J Physiol Pharmacol 2013; 64: 177-183.